Halozyme Therapeutics Inc (HALO)

[maumar]

The fact that PEGPH20 was discontinued for about 3 months complicates things. Any surprises here? Was the market expecting a bigger difference in OS between the two arms? PFS and DoR especially seem good and one would think this should cause longer OS.

"Dr. Andrea Bullock, attending physician in Gastrointestinal Oncology at Beth Israel Deaconess Medical Center and an Instructor in Medicine at Harvard University said: "As one of the highest enrollers in the HALO 202 study, I am encouraged by the final data from Stage One in the HA-high patients. While the sample size remains small, the median PFS and ORR continue to favor the PEGPH20 combination treatment arm compared to the standard of care AG arm. I look forward to the Stage Two results later this year and to participating in the phase 3 global study very soon." "